Clinical trials of the African swine fever vaccine are progressing well

June 10, the China Science Journal learned from the Chinese Academy of Agricultural Sciences 2017-2020 major scientific progress launch, independently developed by Harbin Veterinary Research Institute of african swine fever vaccine environmental release and clinical trials are progressing smoothly.
After the outbreak of swine fever in Africa in China, in accordance with the unified deployment of the Party Group of the Ministry of Agriculture and Rural Affairs, the Chinese Academy of Agricultural Sciences fully organized and carried out scientific and technological research on the prevention and control of swine fever in Africa, and successively completed the laboratory research and industrialization intermediate trial work of the African swine fever vaccine, and a gene-missing vaccine showed good safety and effectiveness. The vaccine strain was approved for environmental release trials by a national review in December 2019 and approved for clinical trials of veterinary biological products by the Ministry of Agriculture and Rural Affairs in March 2020, and approved for clinical trials at three breeding bases in Heilongjiang, Xinjiang and Henan. Harbin Veterinary Research Institute in accordance with the approved test program, scientific and rigorous progress, achieved preliminary results.
environmental release test was carried out smoothly. The team began environmental release trials of vaccine strains in March, overcoming adverse factors such as local extreme low temperatures and outbreaks of new coronary pneumonia. Up to now, the vaccination piglets are in good growth condition, no abnormal clinical condition, the vaccination sow is in good condition, no abnormal clinical performance, no abnormal hair, no abortion. Immune pigs have no vaccine toxic emissions and no horizontal transmission. After immunization, most sows have been born, the immunization group and the control group yield, stillbirth rate is not significantly different, piglet growth is good.
clinical trials are progressing well. According to the clinical trial plan, clinical trials of vaccines were initiated in early April, early May and early June at three bases in Heilongjiang, Henan and Xinjiang, with a total of about 3,000 pigs tested. Up to now, the safety aspect: the growth status of immune piglets is good, no obvious adverse clinical reactions, the piglets vaccinated were examined by caesarean section, there were no obvious pathological changes, no vaccine toxic emissions, no horizontal transmission, the overall death rate was less than 1%, and there was no significant difference between the immune group and the control group pigs. Clinical effectiveness trials are under way.
next step, the Chinese Academy of Agricultural Sciences will implement the unified deployment of the Ministry of Agriculture and Rural Affairs on the prevention and control of swine fever in Africa, and accelerate the development of vaccines in accordance with the requirements of animal vaccine biosecurity management and veterinary drug review.